Sustainable Food Packaging Solutions You Can Trust
1. Sugarcane Bagasse Tableware
Crafted from the natural by-product of sugarcane processing, our bagasse tableware offers an eco-friendly alternative to conventional plastics. Lightweight yet sturdy, these compostable products include plates, bowls, clamshell containers, trays, and cups—perfect for foodservice businesses aiming to reduce their environmental footprint without compromising on quality.
2. Cornstarch Tableware
Our cornstarch-based tableware is completely biodegradable and serves as a plant-based alternative to traditional plastic cutlery and containers. This includes clamshell boxes, plates, bowls, cups, and utensils designed to provide a guilt-free dining experience for your customers.
3. Paper Food Packaging
From paper cups and soup bowls to salad bowls, takeout boxes, and eco-friendly paper bags, our paper packaging solutions are not only recyclable but also compostable. These options help elevate your brand's image by promoting a commitment to sustainable practices.
4. Biodegradable Cutlery
We offer spoons, forks, knives, and sporks made from cornstarch and PLA, ensuring your customers enjoy a fully compostable dining experience. Our cutlery combines convenience with environmental responsibility.
BioLeaderPack is committed to maintaining the highest standards of quality and sustainability. Our products hold globally recognized certifications, including: ISO 9001
FDA
EN13432
ASTM D6400
OK Compost
BPI
BRC
NSF
These certifications guarantee that every product we deliver meets strict quality and environmental safety requirements.
We understand that every brand is unique. That's why BioLeaderPack offers customized packaging solutions designed to meet your specific requirements. From product specifications to branded packaging, we collaborate closely with you to create eco-friendly packaging that enhances your brand identity and appeals to your target audience. Sustainability: 100% biodegradable and compostable products that help reduce your environmental impact.
100% biodegradable and compostable products that help reduce your environmental impact. Quality: Premium materials and manufacturing processes that ensure durability and safety.
Premium materials and manufacturing processes that ensure durability and safety. Customization: Tailored solutions that reflect your brand's unique vision and goals.
Tailored solutions that reflect your brand's unique vision and goals. Global Compliance: International certifications that assure quality and regulatory adherence.
If you're looking to align your foodservice business with sustainable and eco-friendly packaging solutions, BioLeaderPack is your ideal partner. Our extensive range of biodegradable and compostable products, backed by global certifications and customizable options, empowers your brand to lead the way in environmental stewardship while delivering outstanding customer experiences.
TIME BUSINESS NEWS
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
First Patient Enrolled in National Cancer Institute's Vanguard Study Evaluating Guardant Health's Shield Multi-Cancer Detection Test
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)'s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant's Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant's Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The Vanguard study was initiated following review and approval by the U.S. Food and Drug Administration (FDA) as part of the NCI's submission for an investigational device exemption (IDE). 'New screening technology like the Shield MCD test has the potential to detect multiple cancers earlier through a simple blood draw,' said Craig Eagle, MD, Guardant Health Global Chief Medical Officer. 'The earlier we can screen and diagnose cancers, the more options we can bring to patients and ultimately the more lives we can save. The Vanguard Study is a critical step in research to evaluate the role of this breakthrough technology in helping reduce cancer deaths.' The Vanguard Study, conducted by the Cancer Screening Research, a new NCI-sponsored clinical trials network, is enrolling individuals ages 45-75 who do not currently have cancer and who have not received a cancer diagnosis in the past five years. All participants will be offered standard cancer screenings as part of their care. Results from the study will inform the design of a much larger randomized controlled trial to evaluate the use of MCD tests for cancer screening. 'Initiation of the Vanguard Study is an exciting milestone, as we look to evaluate a new way to screen for cancer,' said Scott Ramsey, M.D., Ph.D., director of the Hutchinson Institute for Cancer Outcomes Research at Fred Hutch Cancer Center and principal investigator for the Vanguard Study. 'The study will help us learn more about multi-cancer detection tests and assess whether they can help people from all backgrounds find cancer early, when it may be easier to treat.' The Shield MCD test recently received Breakthrough Device Designation from the FDA for the multi-cancer screening of multiple cancer types including bladder, colorectal, esophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older who are at typical average risk for cancer. The FDA grants Breakthrough Device designation to a limited set of qualifying devices that have the potential to provide more effective treatment or diagnosis of life-threatening diseases, such as cancer, than current options. The goal of the FDA's Breakthrough Devices Program is to provide patients and healthcare providers with timely access to medical devices by speeding up their development, assessment and review. For more information, please visit the Fred Hutch Cancer Center Vanguard Study website. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
Business Wire
2 hours ago
- Business Wire
Atara Biotherapeutics Provides Regulatory and Business Updates on
THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has resubmitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tabelecleucel (EBVALLO™ or tab-cel ®) indicated as monotherapy for treatment of adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy. There are no FDA approved therapies in this treatment setting. 'The BLA resubmission for tab-cel represents the collaborative efforts with our partner, Pierre Fabre Laboratories, to address the third-party manufacturing facility observations outlined in the January 2025 Complete Response Letter,' said Cokey Nguyen, President and Chief Executive Officer of Atara. 'We look forward to continued engagement with the FDA throughout its review and with Pierre Fabre Laboratories as they actively prepare for the potential launch of this innovative therapy in the U.S.' Tab-cel is an allogeneic, EBV-specific T-cell immunotherapy designed to target and eliminate EBV-infected cells. The BLA is supported by pivotal and supportive data covering more than 430 patients treated with tab-cel across multiple life-threatening diseases, including the latest pivotal ALLELE study data that demonstrated a statistically significant 48.8% Objective Response Rate (ORR) (p<0.0001) and favorable safety profile consistent with previous analyses. Tab-cel has been granted Breakthrough Therapy Designation for the treatment of rituximab-refractory EBV-associated lymphoproliferative disease by the U.S. FDA and has orphan drug designation for the treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disorders. Corporate Updates Tab-cel Transition Activities: The company is finalizing the transfer of the following clinical studies associated with tab-cel: NCT03394365: Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE) NCT04554914: A Study to Evaluate Tabelecleucel in Participants with Epstein-Barr Virus-associated Diseases. This study is a multicenter, multicohort, open-label, single-arm, Phase 2 study investigating the efficacy and safety of tabelecleucel for the treatment of EBV-associated diseases. Upon completion substantially all operational activities and associated costs related to tab-cel will transfer to Pierre Fabre Laboratories. The sponsorship of the BLA continues to be maintained by Atara. Cash Runway and Future Tabelecleucel (Tab-cel®) Milestone and Royalty Income: Atara projects that its cash, cash equivalents and short-term investments of approximately $22M as of June 30, 2025, combined with the cost reduction initiatives implemented in the first half of 2025, will enable funding of all currently planned operations, including one-time restructuring costs, into the first quarter of 2026, that Atara believes will be sufficient to fund the ongoing activities required to achieve potential BLA approval. Additionally, under its commercialization agreement with Pierre Fabre Laboratories, Atara is eligible to receive a $40 million milestone payment upon FDA approval of the tab-cel BLA, as well as significant double-digit tiered royalties as a percentage of net sales, and milestones related to commercial sales of EBVALLO. The estimate of our cash, cash equivalents and short-term investments as of June 30, 2025, is preliminary, has not been audited and it is subject to change upon completion of our financial statement closure procedures. Our independent registered public accounting firm has not audited or completed any procedures with respect to this estimate. Such estimates are based on assumptions and plans that are subject to change and such changes could materially impact our expected cash runway. These assumptions include the completion of specific development and regulatory activities by us and actions taken by third parties, and are, therefore, uncertain at this time. Any delay in these activities will create additional expenses and cash needs for us. We have not yet completed our quarter-end financial close process for the quarter ended June 30, 2025. This estimate of our cash, cash equivalents and short-term investments as of June 30, 2025, is preliminary and is subject to change upon completion of our financial statement closing procedures. Additional information and disclosure would be required for a more complete understanding of our financial position and results of operations as of and for the quarter ended June 30, 2025. About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases. Atara is headquartered in Southern California. For more information, visit and follow @Atarabio on X and LinkedIn. Forward-Looking Statements This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding: (1) the development, timing and progress of tab-cel, including the resubmission of the BLA and potential indications, the timing for FDA review of any resubmission of the BLA, the potential characteristics and benefits of tab-cel, and the results of, and prospects for, the global partnership with Pierre Fabre Laboratories involving tab-cel, and the potential financial benefits to Atara as a result of the global partnership with Pierre Fabre Laboratories, including the receipt, timing and amount of any payments to be received by Atara thereunder; (2) Atara's estimate of its cash, cash equivalents, and short-term investments as of June 30, 2025, as well as Atara's cash runway, receipt of potential milestone payments, and operating expenses, including Atara's ability to fund its planned operations into the first quarter of 2026; and (3) Atara's planned transition of substantially all remaining activities relating to tab-cel to Pierre Fabre Laboratories and the timing thereof. Because such statements deal with future events and are based on Atara's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks related with the timing of the transfer of substantially all operational activities related to tab-cel to Pierre Fabre Laboratories, with any potential delay creating additional expenses and cash needs for Atara; risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; risks related to FDA feedback and the ability of Atara, Pierre Fabre Laboratories and Pierre Fabre Laboratories third-party manufacturer to address issues identified in the Complete Response Letter (CRL); our ability to access capital, and the sufficiency of Atara's cash resources and access to additional capital on favorable terms or at all; risks and uncertainties related to Atara's financial close and audit procedures; and other risks and uncertainties affecting Atara, including those discussed in Atara's filings with the Securities and Exchange Commission, including in the 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. Except as otherwise required by law, Atara disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.
The Hill
3 hours ago
- The Hill
Popular yogurt recalled; could contain sharp plastic pieces
(WJW) – A popular yogurt company is recalling more than a dozen of its varieties due to the potential presence of plastic pieces that could have sharp edges and cause choking, as seen in a recall alert published by the Food and Drug Administration (FDA). Bread sold at Walmart and Kroger recalled According to the recall alert, Danone U.S. is voluntarily recalling all flavors and sizes of YoCrunch products currently sold at retail stores nationwide. Danone says consumers have reported finding plastic pieces in the 'dome toppers,' which are separate compartments containing the yogurts' toppings. Officials say only the separately packaged toppers are affected — not the separately packaged yogurt. KFC offers free buckets of chicken in 'comeback' 'The plastic pieces are transparent, may have sharp edges, and could present a risk to consumers because some pieces are between 7 and 25 mm in length,' reads the alert. 'The company is working swiftly with retail partners to remove the impacted product from shelves, while it works to address the issue and bring back the YoCrunch® products so many people enjoy.' Impacted product names and code dates, as provided by the FDA, are below. YOCRUNCH STRAW W/GRANOLA 6OZ (UPC 46675000105) 2025.07.07, 2025.07.12, 2025.07.26, 2025.08.03, 2025.08.08, 2025.08.19, 2025.08.22, 2025.08.30, 2025.09.04 YOCRUNCH VANILLA W/M&M 6OZ (UPC 46675000792) 2025.07.11, 2025.07.14, 2025.07.25, 2025.08.07, 2025.08.11, 2025.08.22, 2025.08.26, 2025.09.03 YOCRUNCH VANILLA W/OREO 6OZ (UPC 46675000808) 2025.07.11, 2025.07.14, 2025.07.24, 2025.07.25 2025.08.06, 2025.08.11, 2025.08.21, 2025.08.26, 2025.09.03 YOCRUNCH STRAW W/M&M 6OZ (UPC 46675000839) 2025.07.12, 2025.07.25, 2025.08.07, 2025.08.22, 2025.09.04 YOCRUNCH VANILLA W/SNICKERS 6OZ (UPC 46675001126) 2025.07.10, 2025.07.24, 2025.08.06, 2025.08.21 YOCRUNCH VANILLA W/TWIX CANDY 6OZ (UPC 46675001133) 2025.07.24, 2025.08.07, 2025.08.21 YOCRUNCH STRAW W/M&M MULTI 4X4OZ (UPC 46675013129) 2025.07.08, 2025.07.12, 2025.07.13, 2025.07.17, 2025.07.18, 2025.07.26, 2025.07.27, 2025.08.02, 2025.08.03, 2025.08.09, 2025.08.11, 2025.08.12, 2025.08.13, 2025.08.15, 2025.08.16, 2025.08.23, 2025.08.24, 2025.08.29, 2025.08.30, 2025.08.31 YOCRUNCH VAN W/COOKIE DOUGH 4X4OZ (UPC 46675013150) 2025.07.17, 2025.08.01, 2025.08.13, 2025.08.29 YOCRUNCH VANI W/SNICKER PCS 4X4OZ (UPC 46675013266) 2025.07.17, 2025.08.01, 2025.08.13, 2025.09.01 YOCRUNCH VANI W/TWIX CANDY 4X4OZ (UPC 46675013273) 2025.07.17, 2025.08.01, 2025.08.14, 2025.08.29 YOCRUNCH VANILLA OREO 4X4OZ (UPC 46675013501) 2025.07.13, 2025.07.14, 2025.07.20, 2025.07.21, 2025.07.24, 2025.07.25, 2025.07.26, 2025.07.31, 2025.08.01, 2025.08.02, 2025.08.08, 2025.08.09, 2025.08.10, 2025.08.11, 2025.08.15, 2025.08.16, 2025.08.23, 2025.08.24, 2025.08.25, 2025.08.30, 2025.08.31 YOCRUNCH VANILLA M&M 4X4OZ (UPC 46675013518) 2025.07.07, 2025.07.09, 2025.07.14, 2025.07.15, 2025.07.16, 2025.07.17, 2025.07.22, 2025.07.23, 2025.07.26, 2025.07.27, 2025.07.28, 2025.08.02, 2025.08.03, 2025.08.05, 2025.08.06, 2025.08.07, 2025.08.10, 2025.08.13, 2025.08.14, 2025.08.16, 2025.08.17, 2025.08.18, 2025.08.19, 2025.08.20, 2025.08.21, 2025.08.22, 2025.08.26, 2025.08.27, 2025.08.28, 2025.08.29, 2025.09.01, 2025.09.02, 2025.09.03, 2025.09.04 YOCRUNCH VAN OREO & M&M FR PK 8X6OZ (UPC 46675014003) 2025.07.12, 2025.07.13, 2025.07.14, 2025.07.15, 2025.07.16, 2025.07.20, 2025.07.21, 2025.07.22, 2025.07.23, 2025.07.24, 2025.07.25, 2025.07.28, 2025.08.02, 2025.08.03, 2025.08.04, 2025.08.05, 2025.08.06, 2025.08.07, 2025.08.10, 2025.08.11, 2025.08.12, 2025.08.13, 2025.08.14, 2025.08.17, 2025.08.18, 2025.08.19, 2025.08.20, 2025.08.21, 2025.08.22, 2025.08.23, 2025.08.25, 2025.08.26, 2025.08.27, 2025.08.28, 2025.08.29, 2025.09.02 YOCRUNCH STR/RAS GRNLA FR PK 8X6OZ (UPC 46675014010) 2025.07.26, 2025.08.23, 2025.08.30 YOCRUNCH STRW W/M&M&OREO FR PK 8X6OZ (UPC 46675026136) 2025.07.22, 2025.08.03, 2025.08.19, 2025.08.29 YOCRUNCH VAN W/SNIC&TWIX FR PK 8X6OZ (UPC 46675026143) 2025.07.14, 2025.07.28, 2025.08.11, 2025.08.26 YOCRUNCH VAN OREO/VAN M&M 18X6OZ CLB (UPC 46675027010) 2025.07.11, 2025.07.19, 2025.07.20, 2025.07.26, 2025.07.27, 2025.07.28, 2025.07.31, 2025.08.01, 2025.08.02, 2025.08.08, 2025.08.09, 2025.08.16, 2025.08.17, 2025.08.23, 2025.08.24, 2025.08.25, 2025.08.30, 2025.08.31 Consumers who have purchased the affected products are urged not to eat them. 'Danone U.S., the makers of YoCrunch, takes every consumer experience seriously and is initiating this voluntary recall in line with its commitment to product quality and consumer safety,' reads the recall alert. For information on refunds, contact the YoCrunch Consumer Care Line at 1-877-344-4886.
